Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics, Inc. (VERA) reported a new insider status update showing that the reporting person, identified as a director of the company, currently has no securities beneficially owned. This Form 3 filing establishes their position as an insider under securities rules without indicating any ownership of Vera Therapeutics stock or derivative securities at this time.
Vera Therapeutics, Inc. announced that its board of directors has appointed James R. Meyers as a Class II director, effective immediately. His initial term will run until the company’s 2026 annual meeting of stockholders, and he has also been appointed to the board’s Audit Committee.
Upon joining the board, Mr. Meyers received a nonstatutory stock option to purchase 25,000 shares of Class A common stock, vesting monthly over three years under the company’s non-employee director compensation policy. He will receive an annual cash retainer of $40,000 for board service and $10,000 for Audit Committee service, pro-rated for 2025. Beginning with the 2026 annual meeting, he will be eligible for an annual option grant for up to the lesser of 14,000 shares or options with a grant date fair value of not more than $400,000, subject to standard vesting tied to continued service.
Vera Therapeutics (VERA) Chief Legal Officer reports share sale. On 11/21/2025, the company’s Chief Legal Officer sold 3,864 shares of Class A common stock in a single reported transaction. The shares were sold at a weighted-average price of $27.8204, with individual trades executed between $27.19 and $28.035.
According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After this transaction, the officer beneficially owns 49,136 shares of Vera Therapeutics common stock, held directly.
Vera Therapeutics (VERA) reported insider activity by its SVP, Finance and Chief Accounting Officer on a Form 4. The filing shows a sale of 15,000 Class A common shares on 11/11/2025 at a weighted-average price of $29.0583. The sale occurred across multiple trades between $29.03 and $29.17.
On 11/13/2025, the officer exercised 10,000 stock options at an exercise price of $3.9396, acquiring 10,000 Class A common shares. Following these transactions, the officer directly beneficially owned 57,839 shares. A related option grant covering the 10,000 shares vests with 1/4 on March 9, 2022 and 1/48 monthly thereafter. The share total includes 893 shares acquired under the company’s 2021 Employee Stock Purchase Plan.
Vera Therapeutics (VERA) reported positive Phase 3 ORIGIN data for atacicept in IgA nephropathy, presented as a late-breaking oral at ASN Kidney Week 2025 and published in The New England Journal of Medicine. Participants on atacicept achieved a 46% reduction from baseline in proteinuria (24-hour UPCR) and a statistically significant, clinically meaningful 42% reduction versus placebo (p<0.0001) at week 36.
Efficacy was consistent across prespecified subgroups, including age, sex, race, region, baseline proteinuria, baseline eGFR, and baseline SGLT2i use. Secondary endpoints improved: Gd-IgA1 decreased by 68% and hematuria resolved in 81% of those with baseline hematuria. Safety across the ORIGIN program appears favorable and comparable to placebo, with fewer serious adverse events on atacicept (1 [0.5%]) than placebo (11 [5%]) and no deaths reported.
Vera Therapeutics (VERA) filed its Q3 2025 10‑Q, showing a larger quarterly net loss as it advances late-stage programs and scales operations. Net loss was $80.3 million (vs. $46.6 million a year ago), driven by higher operating expenses of $83.9 million with research and development at $56.5 million and general and administrative at $27.5 million. Basic and diluted net loss per share was $1.26.
Cash, cash equivalents and marketable securities were $497.4 million as of September 30, 2025, compared with $640.9 million at year-end 2024. Year-to-date net cash used in operating activities was $171.1 million. The company reiterated it believes its liquidity will fund operations for at least the next 12 months.
Vera refinanced its debt and entered a new loan facility of up to $500.0 million on June 2, 2025, with $75.0 million funded at closing and additional tranches available upon milestones and lender discretion. Long-term debt carried value was $74.6 million. The company highlighted positive primary endpoint results from the pivotal ORIGIN 3 Phase 3 trial of atacicept in IgAN and noted FDA Breakthrough Therapy Designation based on earlier Phase 2b data.
Vera Therapeutics (VERA) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1 and includes recent corporate updates.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. Item 9.01 lists the exhibits. The report was signed by Sean Grant, Chief Financial Officer, on November 5, 2025.
Kynam Capital Management, LP, Kynam Capital Management GP, LLC and individual Yue Tang report shared beneficial ownership of 3,426,887 shares of Vera Therapeutics Class A common stock, representing 5.37% of the class. The filing shows no sole voting or dispositive power; instead the reporting persons disclose shared voting and shared dispositive power over the full block of shares.
The signatories certify the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing identifies the reporting persons and their citizenships but does not name any group members or subsidiaries as acquiring parties.
Vera Therapeutics (Nasdaq: VERA) filed an 8-K announcing a new Sales Agreement with TD Securities (USA) LLC (TD Cowen) dated 5 Aug 2025. The arrangement establishes an at-the-market (ATM) equity program permitting the company to issue and sell up to $200 million of Class A common stock under its effective shelf registration statement (Form S-3, File No. 333-282861).
TD Cowen will act as sales agent and/or principal, executing ordinary-course, block or negotiated transactions on Nasdaq or other trading venues. The company will pay a commission of up to 3.0 % of gross proceeds. Vera is under no obligation to sell shares, and either party may terminate the agreement by written notice. The filing simultaneously terminates the prior Sales Agreement dated 3 Jun 2022.
The program enhances funding flexibility without adding debt but could create dilution and share-price overhang if the full $200 million capacity is utilized.